Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Kern

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
CNS Spectrums|April 1, 2024
Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health QuestionnaireJennifer Kern Sliwa, Ronaldo R Naranjo, Ibrahim Turkoz, et al.
Journal of Managed Care & Specialty Pharmacy|April 1, 2020
Pitfalls of Cost-Effectiveness Analysis in Practice: A TRD Case Example in the United States with Esketamine Versus Oral AntidepressantsSwapna Karkare, Hoa H Le, John J Sheehan, et al.
Neuropsychiatric Disease and Treatment|March 16, 2013
Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychoticsLarry Alphs, Cynthia A Bossie, Jennifer Kern Sliwa, et al.
Clinical Pharmacology : Advances and Applications|August 14, 2012
Management of antipsychotic treatment discontinuation and interruptions using model-based simulationsMahesh N Samtani, John J Sheehan, Dong-Jing Fu, et al.
Perspectives in Psychiatric Care|February 16, 2018
An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitateJennifer Kern Sliwa, Adam Savitz, Isaac Nuamah, et al.
International Clinical Psychopharmacology|March 2, 2018
Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophreniaArun Singh, Srihari Gopal, Edward Kim, et al.
Current Drug Safety|November 5, 2010
Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databasesLarry Alphs, Srihari Gopal, Keith Karcher, et al.
CNS Drugs|January 28, 2021
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An OverviewChristoph U Correll, Edward Kim, Jennifer Kern Sliwa, et al.
Schizophrenia (Heidelberg, Germany)|February 25, 2022
Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychoticsChristoph U Correll, Amber Martin, Charmi Patel, et al.
Plastic and Reconstructive Surgery. Global Open|January 22, 2024
Exploration of the Utility of the Generic ICHOM Standard Set Measures in Evaluating the Speech of Patients with Cleft Lip/PalateAmanda C Del Risco, Kristina Dunworth, Banafsheh Sharif-Askary, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
CNS Spectrums|April 1, 2024
Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health QuestionnaireJennifer Kern Sliwa, Ronaldo R Naranjo, Ibrahim Turkoz, et al.
Journal of Managed Care & Specialty Pharmacy|April 1, 2020
Pitfalls of Cost-Effectiveness Analysis in Practice: A TRD Case Example in the United States with Esketamine Versus Oral AntidepressantsSwapna Karkare, Hoa H Le, John J Sheehan, et al.
Neuropsychiatric Disease and Treatment|March 16, 2013
Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychoticsLarry Alphs, Cynthia A Bossie, Jennifer Kern Sliwa, et al.
Clinical Pharmacology : Advances and Applications|August 14, 2012
Management of antipsychotic treatment discontinuation and interruptions using model-based simulationsMahesh N Samtani, John J Sheehan, Dong-Jing Fu, et al.
Perspectives in Psychiatric Care|February 16, 2018
An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitateJennifer Kern Sliwa, Adam Savitz, Isaac Nuamah, et al.
International Clinical Psychopharmacology|March 2, 2018
Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophreniaArun Singh, Srihari Gopal, Edward Kim, et al.
Current Drug Safety|November 5, 2010
Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databasesLarry Alphs, Srihari Gopal, Keith Karcher, et al.
CNS Drugs|January 28, 2021
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An OverviewChristoph U Correll, Edward Kim, Jennifer Kern Sliwa, et al.
Schizophrenia (Heidelberg, Germany)|February 25, 2022
Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychoticsChristoph U Correll, Amber Martin, Charmi Patel, et al.
Plastic and Reconstructive Surgery. Global Open|January 22, 2024
Exploration of the Utility of the Generic ICHOM Standard Set Measures in Evaluating the Speech of Patients with Cleft Lip/PalateAmanda C Del Risco, Kristina Dunworth, Banafsheh Sharif-Askary, et al.
Pageof 3